Natural Compounds: Co-Delivery Strategies with Chemotherapeutic Agents or Nucleic Acids using Lipid-Based Nanocarriers

Abstract

Cancer is one of the leading causes of death, and latest predictions indicate that cancer- related deaths will increase over the next few decades. Despite significant advances in conventional therapies, treatments remain far from ideal due to limitations such as lack of selectivity, non-specific distribution, and multidrug resistance. Current research is focusing on the development of several strategies to improve the efficiency of chemotherapeutic agents and, as a result, overcome the conventional therapies challenges. In this regard, combined therapy with natural compounds and other therapeutic agents, such as chemotherapeutics or nucleic acids, has recently emerged as a new strategy for tackling the drawbacks of conventional therapies. Taking this strategy into consideration, the co-delivery of the above-mentioned agents in lipid-based nanocarriers provide some advantages by improving the potential of the therapeutic agents carried. This review encompassed different strategies associated with combined therapy, at the same time highlighting the most recent advances and outstanding advantages of lipid-based nanocarriers for achieving a promising combination therapy that may overcome cancer treatment challenges.

Codelivery of CPT and siPHB1 with GSH/ROS Dual-Responsive Hybrid Nanoparticles Based on a [12]aneN3-Derived Lipid for Synergistic Lung Cancer Therapy

“…35−38 Despite extensive reports on codelivery systems, there is a considerable gap in terms of optimal drug combinations, controlled release profile, and effectivity between the extensive research articles in this field and nanomedicine on the market. 39,40 Keeping the above-mentioned studies in mind, three ROSresponsive amphiphiles were rationally designed and synthesized, in which CPT-modified phenylborate ester was connected with a macrocyclic polyamine triazole- [12]aneN 3 moiety through different lengths of alkyl chains (with 6, 9, 12 carbon chains for CBN1−CBN3, respectively). In general, the performance of traditional fluorogens is highly limited due to the aggregation-caused quenching (ACQ) problem, which blocks their biomedical application.…”